$3.50
5.42% today
Nasdaq, Dec 04, 10:18 pm CET
ISIN
US36269B1052
Symbol
GANX

Gain Therapeutics Inc Stock price

$3.50
+1.84 110.84% 1M
+1.51 75.88% 6M
+1.34 62.04% YTD
+1.66 90.22% 1Y
+0.21 6.38% 3Y
-7.50 68.18% 5Y
-7.50 68.18% 10Y
-7.50 68.18% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
+0.18 5.42%
ISIN
US36269B1052
Symbol
GANX
Industry

Key metrics

Basic
Market capitalization
$127.7m
Enterprise Value
$119.3m
Net debt
positive
Cash
$8.8m
Shares outstanding
36.0m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
21.6
Financial Health
Equity Ratio
60.5%
Return on Equity
-278.1%
ROCE
-
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-22.1m
Net Income
- | $-23.9m
Free Cash Flow
$-17.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -8.6%
Net Income
- | -16.9%
Free Cash Flow
18.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.5
Short interest
5.1%
Employees
24
Rev per Employee
$0.0
Show more

Is Gain Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Gain Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Gain Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Gain Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Gain Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.70 9.70
10% 10%
-
- Research and Development Expense 11 11
8% 8%
-
-20 -20
9% 9%
-
- Depreciation and Amortization 0.08 0.08
0% 0%
-
EBIT (Operating Income) EBIT -20 -20
9% 9%
-
Net Profit -20 -20
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gain Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gain Therapeutics Inc Stock News

Neutral
GlobeNewsWire
14 days ago
GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced mouse PD model GT-02287 improves mitochondrial function by facilitating GCase trafficking to the mitochondria in patient-derived fibroblasts harboring GBA1 mutation BETHESDA, Md., Nov....
Neutral
GlobeNewsWire
22 days ago
Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson's Disease with or without GBA1 mutations during 3Q 2025 Received approval from the Australian health authorities to extend the dur...
Positive
Seeking Alpha
28 days ago
Gain Therapeutics achieved functional improvement in Parkinson's patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287's mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX's $66 million market cap is seen as deeply undervalued given positive trial data, large mar...
More Gain Therapeutics Inc News

Company Profile

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Head office United States
CEO Gene Mack
Employees 24
Founded 2017
Website www.gaintherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today